Belvedere Trading’s Nektar Therapeutics NKTR Stock Holding History

Belvedere Trading’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,473	Closed	-$102K	–	498
2022 Q1	$102K	Buy	+1,473	New	+$218K	﹤0.01%	326

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Belvedere Trading's NKTR Position: Q2 2022 in Review

Belvedere Trading sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 3,013 shares — an estimated $209K sold.

Belvedere Trading first reported a position in NKTR in Q1 2022 and held it in 1 quarter. The position peaked at $209K in Q1 2022. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Belvedere Trading reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Belvedere Trading sold 3,013 Nektar Therapeutics shares in Q2 2022, an estimated $209K.
Belvedere Trading first reported a position in Nektar Therapeutics in Q1 2022 and held it in 1 quarter.
Belvedere Trading's Nektar Therapeutics position peaked at $209K in Q1 2022.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Belvedere Trading's 13F filing for Q2 2022, filed 21 Jul 2022.